Back to HAE
Dr. Mark Popovsky Receives Prominent Award for Leadership in Transfusion Medicine

BRAINTREE, Mass., Oct. 26 /PRNewswire-FirstCall/ -- Haemonetics Corporation (NYSE: HAE) announced today that Dr. Mark Popovsky, Vice President and Chief Medical Officer, has been awarded the Emily Cooley Memorial Award and Lectureship by AABB. The Memorial Award was founded as a lectureship in 1963 and is given annually to a person who has demonstrated teaching ability and made a major contribution to the fields of immunohematology, transfusion medicine, and cellular therapies.

"The Emily Cooley Memorial Award and Lectureship is an excellent recognition of Dr. Popovsky's dedication to and impact on the transfusion industry. We are honored to have Dr. Popovsky as part of our team and congratulate him on this award," said Brian Concannon, President and CEO of Haemonetics.

Dr. Popovsky joined Haemonetics in 2000 as Corporate Medical Director and President of the Cell Processing Division. In addition to his work at Haemonetics, he is currently an Associate Clinical Professor of Pathology at Harvard Medical School and Beth Israel Deaconess Medical Center. Dr. Popovsky currently serves on the editorial board of 5 journals. He has authored, or co-authored, over 375 publications in transfusion medicine and pathology. He is editor and co-editor of two reference books in transfusion medicine. In 2004, he served in Nigeria as a member of the U.S. President's Emergency Plan for AIDS Relief delegation to that country.

Prior to Haemonetics, Dr. Popovsky was with the American Red Cross, New England Region, where he held the positions of Medical Director and then Chief Executive Officer. He also served as Director of the Transfusion and Intravenous Services at the Mayo Clinic. Dr. Popovsky is an honors graduate of the University of Vermont, College of Medicine.

About Haemonetics

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Together, our devices and consumables, IT products, and consulting services deliver a suite of business solutions to help our customers improve clinical outcomes and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site at http://www.haemonetics.com.

    Contact:
    Julie Fallon
    Tel. (781) 356-9517
    Alt. Tel. (617) 320-2401

SOURCE Haemonetics Corporation

Copyright (2009) PR Newswire. All Rights Reserved.
Back to HAE
Wikinvest © 2006, 2007, 2008, 2009. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki